The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
|Podcasts|March 15, 2019
Spotlight on Clinical Scenarios in Rectal Adenocarcinoma
Author(s)Onclive Team
We sat down with Marwan Fakih, MD, a professor in the Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations at the Comprehensive Cancer Center, to discuss a clinical scenario he faced in practice, and how he used the latest data available to inform his treatment for his patient.
Advertisement
We sat down with Marwan Fakih, MD, a professor in the Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations at the Comprehensive Cancer Center, to discuss a clinical scenario he faced in practice, and how he used the latest data available to inform his treatment for his patient.
Advertisement
Related to this article
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5